Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines

Journal of Immunotherapy

Volumn 39, Issue 4, 2016, Pages 171-180

  Liu, Jingwei ^a   Zhang, Shurong ^b   Hu, Yuefeng ^c   Yang, Zhaomin ^a   Li, Jingpo ^a   Liu, Xuesong ^a   Deng, Lijuan ^a   Wang, Yue ^a   Zhang, Xiaoyan ^a   Jiang, Ting ^a   Lu, Xu ^a,d  

^a Beijing Biohealthcare Biotechnology Co Ltd   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Beijing Shunyi Hospital Affiliated to China Medical University   (China)

^d Center for Epidemiological Research   (China)

Author keywords

Colorectal cancer; Cytotoxic lymphocytes; PD 1; T cell exhaustion; Tim 3

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 2; MUCIN 3; PROGRAMMED DEATH 1 LIGAND 1; T LYMPHOCYTE IMMUNOGLOBULIN MUCIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; CYTOKINE; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CANCER CELL; CANCER PATIENT; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EX VIVO STUDY; EXHAUSTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; CELL CULTURE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; TRANSPLANTATION;

ANTIBODIES, BLOCKING; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY;

EID: 84964853563     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000122     Document Type: Article

References (35)

1. Schirrmacher V, Fournier P, Schlag P. Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines. 2014;13:117-130.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
4. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715-727.
5. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137-1146.
6. Izhak L, Ambrosino E, Kato S, et al. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res. 2013;73:1514-1523.
7. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275-4280.
8. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
9. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687.
10. Thoulouze MI, Sol-Foulon N, Blanchet F, et al. Human immunodeficiency virus type-1 infection impairs the formation of the immunological synapse. Immunity. 2006;24:547-561.
11. Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27:670-684.
12. Kandalaft LE, Motz GT, Duraiswamy J, et al. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 2011;30: 141-151.
13. Fourcade J, Sun Z, Pagliano O, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012;72:887-896.
14. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11: 1307-1326.
15. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
16. Blackburn SD, Shin H, Freeman GJ, et al. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008;105:15016-15021.
17. Gehring AJ, Ho ZZ, Tan AT, et al. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virusrelated hepatocellular carcinoma. Gastroenterology. 2009;137: 682-690.
18. Golden-Mason L, Palmer BE, Kassam N, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol. 2009;83:9122-9130.
19. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205:2763-2779.
20. Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415:536-541.
21. Fourcade J, Sun Z, Pagliano O, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res. 2014;74:1045-1055.
22. Xu B, Yuan L, Gao Q, et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget. 2015;6:20592-20603.
23. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
24. Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol. 2012;91: 53-58.
25. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419-426.
26. Schlom J. Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm. 2012;27:2-5.
27. Marten A, Ziske C, Schottker B, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001;24: 502-510.
28. Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011;34:409-418.
29. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6:3479-3492.
30. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
31. Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239-245.
32. Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, et al. The costimulatory role of TIM molecules. Immunol Rev. 2009;229: 259-270.
33. Moon EK, Wang LC, Dolfi DV, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20:4262-4273.
34. Poehlein CH, Haley DP, Walker EB, et al. Depletion of tumorinduced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol. 2009;39:3121-3133.
35. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci. 2009;1174:99-106.